Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 1.00 |
| ▸ | RXRB | P28702 | 9/20 | 0.68 |
| ▸ | RXRG | P48443 | 9/20 | 0.68 |
| ▸ | RARB | P10826 | 5/20 | 0.67 |
| ▸ | RARG | P13631 | 5/20 | 0.67 |
| ▸ | RARA | P10276 | 4/20 | 0.67 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.60 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717021 | 0.87 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7521288 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6907698 | 0.85 | RXRA (0.74) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL3453249 | 0.82 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL30012842 | 0.82 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6889399 | 0.82 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7762990 | 0.82 | RXRA (0.68) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926941 | 0.81 | RXRA (0.68) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926940 | 0.81 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6676473 | 0.81 | RXRA (0.67) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | claimed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | claimed |
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | claimed |
| EP-0637297-B1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 2000-08-23 | — | — | EP | claimed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | claimed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | NCOR1, NR4A2, NR4A3 | RXRA 4/4885RXRB 7/4885RXRG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.